Table 1.
Baseline demographic and disease characteristics
| Characteristic | FL | GCB DLBCL | Non‐GCB DLBCL | All DLBCL | All patients |
|---|---|---|---|---|---|
| n = 27 | n = 16 | n = 16 | n = 34a | n = 61b | |
| Median age (range), years | 57 (31‐79) | 68 (22‐82) | 67 (39‐82) | 67 (22‐82) | 60 (22‐82) |
| Sex, n (%) | |||||
| Male | 17 (63) | 12 (75) | 8 (50) | 21 (62) | 38 (62) |
| Female | 10 (37) | 4 (25) | 8 (50) | 13 (38) | 23 (38) |
| Race, n (%) | |||||
| White | 23 (85) | 15 (94) | 15 (94) | 32 (94) | 55 (90) |
| Black/African American | 1 (4) | 0 | 1 (6) | 1 (3) | 2 (3) |
| Unknown | 3 (11) | 1 (6) | 0 | 1 (3) | 4 (7) |
| ECOG performance status, n (%) | |||||
| 0 | 15 (56) | 7 (44) | 9 (56) | 16 (47) | 31 (51) |
| 1 | 12 (44) | 9 (56) | 7 (44) | 18 (53) | 30 (49) |
| ≥2 | 0 | 0 | 0 | 0 | 0 |
| De novo DLBCL, n (%) | NA | 16 (100) | 16 (100) | 34 (100) | NA |
| Bulky disease ≥5 cm, n (%) | |||||
| Yes | 10 (37) | 7 (44) | 7 (44) | 14 (41) | 24 (39) |
| No | 14 (52) | 6 (38) | 7 (44) | 14 (41) | 28 (46) |
| Unknown | 3 (11) | 3 (19) | 2 (13) | 6 (18) | 9 (15) |
| B symptoms, n (%) | |||||
| Yes | 9 (33) | 3 (19) | 4 (25) | 7 (21) | 16 (26) |
| No | 18 (67) | 12 (75) | 12 (75) | 26 (76) | 44 (72) |
| Unknown | 0 | 1 (6) | 0 | 1 (3) | 1 (2) |
| WHO grade of FL, n (%) | |||||
| 1 | 2 (7) | NA | NA | NA | NA |
| 2 | 15 (56) | NA | NA | NA | NA |
| 3A | 10 (37) | NA | NA | NA | NA |
| 3B | 0 | NA | NA | NA | NA |
| Number of prior regimens, n (%) | |||||
| 1 | 6 (22) | 2 (13) | 1 (6) | 3 (9) | 9 (15) |
| ≥2 | 21 (78) | 14 (88) | 15 (94) | 31 (91) | 52 (85) |
| Median number of prior regimens (range) | 2.0 (1.0‐4.0) | 2.0 (1.0‐4.0) | 3.0 (1.0‐7.0) | 2.5 (1.0‐7.0) | 2.0 (1.0‐7.0) |
| Disease status following completion of last prior regimen, n (%) | |||||
| Relapsed from CR | 14 (52) | 2 (13) | 7 (44) | 9 (26) | 23 (38) |
| Relapsed from PR | 2 (7) | 1 (6) | 2 (13) | 4 (12) | 6 (10) |
| Refractory (SD or PD) | 11 (41) | 13 (81) | 7 (44) | 21 (62) | 32 (52) |
| Median time from initial diagnosis to first dose (range), months | 49.9 (9.8‐362.5) | 14.1 (6.0‐104.1) | 19.5 (7.3‐86.7) | 14.7 (6.0‐104.1) | 26.1 (6.0‐362.5) |
Abbreviations: CR, complete response; DLBCL, diffuse large B‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; GCB, germinal center B‐cell; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease; WHO, World Health Organization.
a
Includes patients with GCB DLBCL, non‐GCB DLBCL, and unspecified DLBCL.
b
Patients who received ≥1 dose of study treatment.